Background
==========

The most common malignancy in the human person is skin cancer. \[[@B1]\]. Australia has the highest incidence of skin cancer in the world \[[@B2]\]. Cutaneous squamous cell carcinoma (cSCC) incidence in Australia is rising. From 1985 to 2002, age-standardised incidence rates of cSCC had increased by 133% \[[@B2]\]. The mortality is also increasing \[[@B3]\]. Some 20% of all skin cancer of the head and neck are cSCC \[[@B4]\]. Only a minority of facial and scalp cSCC will metastasise to regional parotid lymph nodes. It is an Australian phenomenon that the most common malignant tumour of the parotid gland is metastatic cSCC \[[@B5]\]. These patients suffer increased morbidity and even mortality if locoregional control is not achieved at first presentation

Definitive treatment of metastatic cSCC to the parotid is a therapeutic challenge requiring multidisciplinary input and multimodality therapy. The purpose of this study was to evaluate our experience in treating metastatic cSCC to the parotid gland in patients presenting to our multidisciplinary head and neck clinic.

Our institutional management policy for this disease is as follows. Parotidectomy with appropriate neck dissection is considered the standard of care for patients with metastatic cutaneous SCC to the parotid gland in our institution. The extent of parotidectomy is based on preoperative clinical and radiologic assessment and follows the definitions of neck dissection defined by Robbins *et al*. \[[@B6]\]. Superficial parotidectomy with facial nerve conservation is appropriate for the majority of patients unless facial nerve infiltration is identified preoperatively or tumour infiltration into the facial nerve is identified at the time of surgery, in which case, total parotidectomy with facial nerve resection is considered. Similarly, if adjacent soft tissue structures such as preauricular skin or external auditory canal are involved clinically or radiologically, then extended resection encompassing the surrounding soft tissues with appropriate local or flap reconstruction is considered. Adjuvant radiotherapy to the parotid bed and ipsilateral neck starting within six weeks of operation is then given. The surgical bed is planned for treatment to 60 to 66 Gy, the neck to 45 to 56 Gy, all in 1.8 to 2 Gy fractions at five fractions per week. Treatment is discontinued if there is significant radiation toxicity. Concurrent chemotherapy was not used routinely in this patient population at this time.

Methods
=======

A retrospective review of patients with metastatic cSCC to the parotid gland who were treated with curative intent at St. Vincent\'s Hospital during a 10-year period (1996 to 2006) was performed. Research was carried out in compliance with the Helsinki Declaration and this project was approved by the St Vincent's Hospital Human Research Ethics Committee approval number 08/108. All patients were evaluated in a multidisciplinary head and neck clinic and all clinical and pathological data was prospectively recorded. Data collected included: age, sex, immune status, primary skin tumour site if available, nodal involvement, margin status, extracapsular extension, perineural invasion, extent of surgery performed and radiotherapy details. Immune-compromised patients included patients with intercurrent haematological malignancies, lymphoma and transplant recipients on long-term immunosuppressive treatment.

Statistical analysis was performed using STATA version 9 (Stata Corp., College Station, TX, USA). Univariate and multivariate analyses were performed using Cox proportional hazards regression mode and overall survival (OS) and disease-specific survival (DSS) were estimated by the Kaplan-Meier method. The OS period was calculated from parotidectomy to date of death or last follow-up. The DSS period was calculated from parotidectomy to date of death from disease or last follow-up.

Multivariate analysis of factors influencing OS and DSS were performed on selected explanatory variables by means of a Cox's proportional hazards regression. A step-wise approach was used to select independent significant covariates. The variables were analysed via a nominal categorization. The probabilities of entry and removal from the multivariate model were set at 0.10 and 0.10, respectively. Prognostic factors that showed significant *P* value of less than 0.1 in univariate analysis were investigated in the multivariate analyses. These were immune suppression, margin status of parotid, parotidectomy and O'Brien P stage \[[@B5]\].

Results
=======

Patient characteristics
-----------------------

Sixty-seven patients that fulfilled the eligibility criteria for this study and their details are summarised in Table [1](#T1){ref-type="table"}. Some 90% of the patients were male and the mean age of the patients was 72.8 years. Forty-one (61%) patients presented with metastatic cSCC to the parotid only while 26 (39%) patients presented with metastatic cSCC to both parotid and ipsilateral cervical lymph nodes. Eight patients (12%) were immune-compromised at the time of surgery. Three patients had non-Hodgkin's lymphoma and five patients had chronic lymphocytic leukemia. Eleven patients had a history of primary lesion that was thought responsible for the parotid nodes.

###### 

Patient characteristics

                             **All**       **Patients with cancer spread to parotid only**   **Patients with cancer spread to parotid and neck**
  -------------------------- ------------- ------------------------------------------------- -----------------------------------------------------
  N                          67            41 (61.2%)                                        26 (38.8%)
  Sex                                                                                         
  Female                     7 (10.4%)     2 (4.9%)                                          5 (19.2%)
  Male                       60 (89.6%)    39 (95.1%)                                        21 (80.8%)
  Age in years (mean ± SD)   72.8 ± 11.5   72.9 ± 11.4                                       72.7 ± 12.0
  Immunosuppression                                                                           
  Immune-compromised         8 (12.1%)     5 (12.2%)                                         3 (12.0%)
  Non-immune-compromised     58 (87.9%)    36 (87.8%)                                        22(88.0%)

Treatment characteristics
-------------------------

All patients underwent parotidectomy. Fifty-three patients had superficial parotidectomy performed while fourteen patients underwent total parotidectomy. Fifty-four patients had an ipsilateral neck dissection performed. Of these twenty-eight had radical neck dissection, thirteen had modified radical neck dissection, twelve had selective neck dissection and one patient had an extended radical neck dissection.

One patient died on the first postoperative day. This patient was excluded from the survival analysis. The remaining sixty-six patients all received planned postoperative adjuvant radiotherapy. All 66 patients received radiotherapy to the parotid bed, and 65 to the ipsilateral neck. The average dose of radiotherapy to the parotid and upper neck was 53.9 Gy (SD: 5.6 Gy), while the lower neck received an average dose of 43.6 Gy (SD: 19.8 Gy). Three received platinum-based concurrent chemotherapy.

Pathologic characteristics
--------------------------

Sixty patients had a complete histopathology report from the parotidectomy available for analysis. The average number of parotid lymph nodes removed was 4.5 while the average number of positive parotid nodes removed was 1.7. The largest parotid node removed was 7 cm with 50% of positive nodes measuring greater than 2 cm. Nine patients (15%) had histological evidence of perineural invasion while thirty-five (57%) patients displayed extra capsular extension in the parotidectomy specimen.

Parotidectomy specimens were also assessed for margin status. Margin status was available in 59 patients and was classified as positive, negative or close (if \< 0.5 mm). Twenty-one patients (35%) had positive margins, twenty-three (38%) were negative and fifteen patients (25%) had close margins.

Overall survival outcomes and associations
------------------------------------------

For the 66 patients, the two-year and five-year overall survival rate was 0.83 and 0.72, respectively. (See Figure [1](#F1){ref-type="fig"}[Additional file 1](#S1){ref-type="supplementary-material"}). Overall survival was only significantly correlated with the extent of parotidectomy (superficial versus total; *P* = 0.0256). Patients that required total parotidectomy had reduced survival compared to those that had superficial parotidectomy performed (See Figure [2](#F2){ref-type="fig"}). O'Brien staging \[[@B5]\] for overall survival was almost significant for P1 versus P2 + P3 (*P* = 0.0531). Parameters of immune suppression, perineural invasion, extracapsular extension, degree of tumour differentiation, number of positive nodes, extent of neck dissection and radiotherapy dosage delivered did not confer prognostic significance.

![**Kaplan-Meier estimated overall survival for all patients**.](1477-7819-10-117-1){#F1}

![**Kaplan-Meier estimated disease-specific survival for all patients**.](1477-7819-10-117-2){#F2}

Disease-specific survival outcomes and associations
---------------------------------------------------

The two-year and five-year disease-free survival rate was 0.91 and 0.83 respectively. (See Figure [3](#F3){ref-type="fig"}, [Additional file 2](#S2){ref-type="supplementary-material"}). The only parameter that significantly correlated with disease-free survival was margin status (Close/negative versus positive *P* = 0.0348). Patients with close or negative margins had improved two-year and five-year survival compared to patients with positive margins (See Figure [4](#F4){ref-type="fig"}). Parameters of immune suppression, perineural invasion, extracapsular extension, degree of tumour differentiation, number of positive nodes, O'Brien staging, extent of neck dissection and radiotherapy dosage delivered did not confer prognostic significance.

![Comparison of Kaplan-Meier estimated overall survivals between patients with different extent of parotidectomy.](1477-7819-10-117-3){#F3}

![**Comparison of Kaplan-Meier estimated disease-specific survival between patients with negative, positive and close parotid margin**.](1477-7819-10-117-4){#F4}

Discussion
==========

Metastatic cSCC to the parotid gland is a relatively common clinical presentation faced by Australian head and neck surgeons and radiation oncologists. Unfortunately, there are no randomised control trials to guide treatment recommendations, and our current management guidelines are based on similar retrospective studies from other Australian institutions.

The survival analysis showed that this cohort had similar survival rates to other studies. Table [2](#T2){ref-type="table"} compares the results of our studies to other institutions. However, the two- and five-year disease-free survival rates of 91% and 83% respectively are slightly higher than other reported series \[[@B5],[@B7]-[@B11]\]. This may be because all of our analyzed patients were treated with surgery with clearance of at least all macroscopic disease, and also radiotherapy to parotid and all but one to the ipsilateral neck. The other studies included patients treated with just radiotherapy or just surgery.

###### 

Comparison to other similar studies

  **Series**                     **Duration**   **Number**   **% Treated with surgery and adjuvant radiotherapy**   **Survival at 5 years**
  ------------------------------ -------------- ------------ ------------------------------------------------------ -------------------------
  O'Brien *et al*. \[[@B5]\]     1990--2002     87           86                                                     63% DSS
  Ch'ng *et al*. \[[@B7]\]       1990--2004     67           67                                                     44% CSS
                                                                                                                    54% DSS
                                                                                                                    79% DFS
  Chua *et al*. \[[@B8]\]        1980--1997     52           100                                                    65% CSS
  Palme *et al*. \[[@B9]\]       1987--1999     126          89                                                     68% DSS
  Dona *et al*. \[[@B10]\]       1983--2000     74           100                                                    72% CSS
  Veness *et al*. \[[@B11]\]     1980--2000     167          87                                                     73% DFS
  Goh *et al*. (current study)   1996--2006     66           100                                                    72% OS
                                                                                                                    83% DSS

*CSS*, cause-specific survival; *DFS*, disease-free survival; *DSS*, disease-specific survival; *OS*, overall survival.

Analysis of prognostic variables showed that patients that underwent total parotidectomy had a significantly worse outcome than patients requiring superficial parotidectomy (superficial versus total; *P* = 0.0256). This would seem logical as patients requiring total parotidectomy had more advanced locoregional disease. This study has also confirmed the adverse prognostic implication of positive margins on disease-free survival (Close/negative versus positive *P* = 0.0348). The five-year disease-free survival of patients with negative parotid margins was 88% compared with 41% for patients with positive parotid margins. This once again highlights the importance of attempting to achieve clear surgical margins. The adverse effect of positive parotid margins in patients with metastatic cSCC has also been identified in other studies \[[@B5],[@B10]\]. Careful preoperative planning with appropriate imaging such as CT and/or MRI scan is recommended when tumour extension outside the parotid gland is suspected. Patients can then be appropriately counseled about the possible need for adjacent soft tissue resection and arrangements for appropriate reconstruction can be made.

The significant effect of immune compromise in this group of patients has been validated in other studies \[[@B12]-[@B14]\]. These patients have significantly worse overall survival than immune-competent patients. Interestingly, when we compared disease-specific survival between these two patient populations no significant survival difference was found.

The role of elective neck dissection also remains controversial. Several Australian studies have demonstrated that approximately one third of patients with metastatic cSCC to the parotid gland with clinically negative necks will have occult metastases identified following neck dissection \[[@B15],[@B16]\]. Selective neck dissection is a relatively straightforward procedure associated with relatively limited morbidity, particularly when combined with parotidectomy. We routinely perform elective supraomohyoid neck dissection in conjunction with parotidectomy. There are, as yet, no randomised control trials comparing adjuvant radiotherapy to elective neck dissection in the treatment of the clinically negative neck in this disease.

Conclusions
===========

Cutaneous squamous cell carcinoma metastatic to the parotid is a challenging condition requiring multidisciplinary assessment and multimodality therapy. This retrospective review performed on 67 patients at St Vincent's Hospital, Sydney, between 1996 and 2006 confirmed the adverse prognostic implication of positive margins on disease-free survival. Immune compromise was not a significant factor in this small group.
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